Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
well, it's up 2.4% right now...
Electromedical Technologies Receives Key Medical Device Certification
https://www.biospace.com/article/releases/electromedical-technologies-receives-key-medical-device-certification/
Ok, I see it now- had to scroll down past the endless 1 share trades. whatever the heck those are
No idea, but what price did it close at? I see .127 on L2 - but don't see any trades at that price
nice base being formed here for next run up
EMED - still king of the 1 share trades.
Biotechs are a different animal. They can go from zero to hero very quickly with the right approvals/partnerships/buyouts. And you can only participate in the hero part if you're holding shares. I'd say there's a decent % of RGBP shareholders who are of that mindset even though RGBP is an OTC stock.
And back up she goes... any volume will SEND this
Thx linkvest.. I'm okay with price movement in either direction right now...still accumulating...
Jumping in GRST here...
You're right - I posted that too quickly without checking it out closely enough - thanks for the catch!
Today's patent: "Item 8.01: On September 23, 2021 Regen Biopharma, Inc. was granted a Notice of Allowance on the Patent application titled “Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans” by the United States Patent and Trademark Office."
They don't need to start paying it back until March, 2022, right? And it's not some huge sum of money.
The idea here is the IP is valuable, such that RGBP will enter into partnerships/JV's and/or buyout...any of which provides the revenue.
If you don't think partnerships or a buyout is possible/probable, then I guess you'd despair over the payment terms. If you do think it's probable (as many here do, including me), then it's not a big deal.
Comes down to what you think of the IP and prospects of Regen monetizing it in some way over the coming months, IMO.
It comes down to the value of the IP.
bid support building up...
EMED wants to go up... and is...
And good morning doc (afternoon for you)
interesting pre-market
And yes, DD on NR2F6 studies worldwide abounds and is directly relevant for the patents RGBP owns. It's real, and it's valuable.
Here's yet another write-up from a few months ago:
Quote:
Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6.
26 May 2021
Abstract
Additional therapeutic targets suitable for boosting anti-tumor effector responses have been found inside effector CD4+ and CD8+ T cells. It is likely that future treatment options will combine surface receptor and intracellular protein targets. Utilizing germline gene ablation as well as CRISPR/Cas9-mediated acute gene mutagenesis, the nuclear receptor NR2F6 (nuclear receptor subfamily 2 group F member 6, also called Ear-2) has been firmly characterized as such an intracellular immune checkpoint in effector T cells. Targeting this receptor appears to be a strategy for improving anti-tumor immunotherapy responses, especially in combination with CTLA-4 and PD-1. Current preclinical experimental knowledge firmly validates the immune checkpoint function of NR2F6 in murine tumor models, which provides a promising perspective for immunotherapy regimens in humans in the near future. While the clinical focus remains on the B7/CD28 family members, protein candidate targets such as NR2F6 are now being investigated in laboratories around the world and in R&D companies. Such an alternative therapeutic approach, if demonstrated to be successful, could supplement the existing therapeutic models and significantly increase response rates of cancer patients and/or expand the reach of immune therapy regimens to include a wider range of cancer entities. In this perspective review, the role of NR2F6 as an emerging and druggable target in immuno-oncology research will be discussed, with special emphasis on the unique potential of NR2F6 and its critical and non-redundant role in both immune and tumor cells.
https://europepmc.org/article/PMC/PMC8197903
Gotta say, it's not particularly important to me if there's a buyout or a series of partnerships/JV's... either would be hugely impactful in terms of advancing the profile of RGBP and increasing the pps.
So, I think these heated discussions about which it is are mostly irrelevant. No one here knows for sure.
I'm here for the $ and based on the evidence, I'd say those who are holding shares will be in great shape over the coming months.
Yet another great 8K. I'm more bullish on RGBP than ever. Could care less about the day to day; I'm not a daytrader. In this one for the PRIZE and bigger $$$. Lawsuit now settled and paid. Scientific data back in the rightful hands. Uplisting forthcoming. Bet biz deal(s) are far advanced or already agreed-to in principal. As you said, Koos can only share so much with the public, legally. He's been setting this one up methodically for some time now- taking care of business one step at a time - and I'm expecting an extremely "fun" fall and winter in RGBP-land!
This IP is GOLD and Koos has the team in place to get the deals done and monetized.
Huge and numerous catalysts in play here - can't beat this set-up in the OTC!
During the coming months I shall endeavor to achieve the following milestones:
1) Settle all outstanding convertible notes payable in order that the Company will have no convertible instruments outstanding.
2) Hire a Chief Scientific Officer
3) Seek out and enter into alliances, co-development agreements and additional licensing agreements with regard to our proprietary mRNA and NR2F6 portfolios.
4) Obtain OTCQB listing for our securities on the OTC Market.
5) Establish a social media presence in order to more easily provide updates to our shareholders
Feels like it's close to clearing those 9's out.
I could well imagine the same. It'll be very interesting to see what the dynamics are come October along those lines. Unprecedented.
GRSO 8's getting chipped away at.
Reminds me of the analysis of NR2F6 therapies by a team of Research Scientists out of the EU from a few years ago, where the language they used seems almost insistent regarding the anti-tumor effects:
Nr2f6 therapies "resulting in striking anti-tumor effects in different advanced mouse models relevant to human cancer."
Quote:
According to all our preclinical data, high NR2F6 expression is likely to critically contribute to the immune-suppressed state of tumor antigen-specific TILs, thus limiting the host’s anti-tumor immune response. Absence of NR2F6, either through genetic ablation in Nr2f6 knockout mice or by the means of siRNA knockdowns, increases the immune system’s ability to mount effective immune responses, resulting in striking anti-tumor effects in different advanced mouse models relevant to human cancer.
https://www.nature.com/articles/s41467-018-04004-2
Pink Current .000 play = $$$
let's chew through those 8's...
moving up tick by tick
This thing just keeps going - great bid support and it's clearly going higher.
EMED showing tons of strength - just wow!
Yep - just the groups looking to accumulate more 6's tapping the 6's hoping to scare some into selling... not very successful so far... likely see those larger bids move into 7's soon enough. Not much action at .0006. .0008's new loading zone.
Is this an actual company sanctioned PR? God forbid!
https://www.ascentsolar.com/ir-asti-news-page.html
It is indeed - wonder if they're finally turning their attn to the share price... this is a good start if so. And there's a ton more they could report.
wicks count!
There is no gap
Nice find gemfinder, from that linked article:
"The mRNA vaccines market is projected to receive notable contribution from the cancer segment that is estimated to claim the leading revenue share over the coming years. The segment's growth is augmented by increasing incidence of cancer. The condition remains one of the major causes of mortalities globally, with the number of new cases annually exceeding 23.6 million by the year 2030."
Gotta love these 1 share buys the MM's are inputting. Not sure I've seen that before.
Big pharma wants in - badly.
Quote:
Novartis weighs entry into mRNA technology, chairman tells paper
ZURICH, July 1 (Reuters) - Swiss drugmaker Novartis NOVN.S could get into the field of messenger ribonucleic acid (mRNA) technology, which has come to the fore in vaccine development during the coronavirus pandemic, Chairman Joerg Reinhardt said in a newspaper interview.
In the Aargauer Zeitung interview, Reinhardt also highlighted the company's resurgent interest in anti-infective products that has also been driven by the pandemic.
"The mRNA technology has proven to be an attractive option in this situation and of course every research company is questioning whether they should invest more in this area," he told the Swiss paper.
"Novartis is doing the same and we are having the discussion this week in the executive committee and then in August in the board of directors," he added without being more specific.
Novartis had joined many other companies in 2018 when it abandoned anti-viral and anti-bacterial research at a facility in California, as it concluded the probability of success was relatively low and wanted to re-direct resources to other areas like gene therapy.
"We are now reassessing that," Reinhardt said, as the pandemic has resurrected the company's interest in anti-infectives.
https://www.nasdaq.com/articles/novartis-weighs-entry-into-mrna-technology-chairman-tells-paper-2021-07-01-0
Yep, and as you said bid support is looking good as well.
Continued nice hits on the ask... only way to accumulate a decent amount of shares here.
Keep in mind the valuation of Translate Bio... their lead candidate treats CF (cystic fibrosis).
[Edit] Compare the global market size of CF to cancer...
---> The global cystic fibrosis therapeutics market size was valued at $5.1B in 2018 and is expected to reach $31.9B by 2027
---> The global oncology drugs market size was valued at $141B in 2019 & is projected to reach $394B by 2027
--------------------------------------------------------
Therefore it stands to reason the pipeline of pre-clinical candidates that treat cancer would be valued at an exponential to candidates that treat CF. (see Kite Pharma's ~$12B acquisition.)
---------------------------------------------------------
The key here is big pharma is in a race to build out their clinical pipelines with next-class mRNA treatments.
Here is a recent example, Sanofi's acquisition of Translate Bio for their mRNA technology for $3.2B.
For comparison purposes, here is a link to Translate's pipeline: https://translate.bio/pipeline/
Quote:
Sanofi Completes Acquisition Of Translate Bio, Accelerating The Application Of MRNA In New Vaccines And Therapeutics
Sep 15, 2021
Sanofi announced the completion of its acquisition of Translate Bio, further accelerating the company’s efforts to develop transformative vaccines and therapies using mRNA technology. The acquisition adds a critical pillar to the company’s mRNA Center of Excellence which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases.
The tender offer for all of the outstanding shares of Translate Bio common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, September 13, 2021. The minimum tender condition and all of the other conditions to the offer have been satisfied and on September 14, 2021, Sanofi accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn.
Following its acceptance of the tendered shares, Sanofi completed its acquisition of Translate Bio through the merger of a wholly owned subsidiary of Sanofi with and into Translate Bio, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Translate Bio continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi.
In connection with the merger, all Translate Bio shares not validly tendered in the tender offer have been converted into the right to receive the same $38 per share in cash, without interest thereon and net of any applicable withholding taxes, that would have been paid had such shares been validly tendered in the tender offer. As of September 14, 2021, Translate Bio common stock will cease to be traded on the NASDAQ Global Select Stock Market.
Morgan Stanley & Co. International plc acted as exclusive financial advisor to Sanofi while Weil, Gotshal & Manges LLP acted as legal counsel. Centerview Partners acted as lead financial advisor to Translate Bio in the transaction, while Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal counsel. Evercore also acted as a financial advisor in this transaction to Translate Bio. MTS Health Partners, LP also gave financial advice to Translate Bio.
https://www.pharmajournalist.com/sanofi-completes-acquisition-of-translate-bio-accelerating-the-application-of-mrna-in-new-vaccines-and-therapeutics/
Holy crap lol